MedTrace Logo

An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)

NCT03955276 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2022-02-15

No results posted yet for this study

Summary

The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement Amendments (CLIA) certified comprehensive genomic analysis. The molecular mutation profile will then be matched to existing, FDA-approved, targeted agents or to existing clinical trials using investigational agents for treatment of patients with incurable hematologic malignancies for whom no effective standard therapy exists or who have either exhausted or are intolerant of standard options.

Conditions

  • Hematologic Cancer

Interventions

OTHER

Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)

Biologically targeted matched treatment (chosen by treating physician)

Sponsors & Collaborators

Principal Investigators

  • Natalie Galanina, MD · UCSD/MCC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-07
Primary Completion
2020-11-20
Completion
2021-01-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03955276 on ClinicalTrials.gov